EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inhibitory immune checkpoints in cancer immunotherapy

Zhenghai Tang iD, André Veillette iD

Science Immunology · 26.09.2025 · 10 (111)

DOI: 10.1126/sciimmunol.adv6870 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Immunology, erschienen am 26.09.2025. Verfasst von Zhenghai Tang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Faculty of Health Sciences, University of Macau, Macau, SAR, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 142 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies and other agents that inactivate immune checkpoints like PD-1 and CTLA-4 have been effective against only certain types of cancer and have had highly variable efficacy in patients. These limitations have hastened investigations of additional checkpoints that can serve as therapeutic targets. Nevertheless, no other approach has yet reached the effectiveness of PD-1 and CTLA-4 inactivation. Recent studies have shown that experimental inhibitory immune checkpoints and the drugs targeting them display unexpected or undesirable mechanisms of action or regulation, thus highlighting previously underappreciated complexities of immune checkpoint–based therapies. Understanding these nuances is crucial for developing more effective and safer therapies. This Review explores the intricacies surrounding inhibitory immune checkpoints and offers insights for improved therapeutic strategies in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansAnimalsCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Cancer Center, Faculty of Health Sciences, University of Macau, Macau, SAR, China.
  • MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau, SAR, China.
  • Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec H2W1R7, Canada.
  • Department of Medicine, McGill University, Montréal, Québec H3G 1Y6, Canada.
  • Department of Medicine, University of Montréal, Montréal, Québec H3T 1J4, Canada.

ORCID-Profile: Zhenghai Tang, André Veillette

Zitieren

APA

Tang, Z., & Veillette, A. (2025). Inhibitory immune checkpoints in cancer immunotherapy. Science Immunology, 10(111). https://doi.org/10.1126/sciimmunol.adv6870

Vancouver

Tang Z, Veillette A. Inhibitory immune checkpoints in cancer immunotherapy. Science Immunology. 2025;10(111). doi:10.1126/sciimmunol.adv6870

BibTeX
@article{Tang2025,
  author = {Tang, Zhenghai and Veillette, André},
  title = {Inhibitory immune checkpoints in cancer immunotherapy},
  journal = {Science Immunology},
  year = {2025},
  volume = {10},
  number = {111},
  doi = {10.1126/sciimmunol.adv6870}
}
Kostenlos starten →